2. Agency for Health Care Policy and Research: Acute Pain Management: Operative or Medical Procedure and Trauma. Clinical Practice Guideline No 1. Rockville, Md: AHCPR Publication no. 92-0032, 1992.
3. Agency for Health Care Policy and Research: Management of Cancer Pain. Clinical Practice Guideline No 3. Rockville, Md: AHCPR Publication no. 94-0592, 1994.
4. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain 4th Edition, American Pain Society, Glenview, Il, pp 31, 1999.
5. Danziger LH, Martin, SJ and Blum RA. Central nervous system toxicity associated with meperidine use in hepatitis disease. Pharmacotherapy 14: 235-8, 1994.
6. Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Roger AG, Inturrisi
CE, Reidenberg MM: Central nervous system excitatory effects of meperidine
in cancer patients. Annals of Neurology 13 (2): 180-185, 1983.
7. Lee F, Cundiff, D. Meperidine vs. morphine in pancreatitis
and cholecystitis. Arch Intern Med 158: 2339, 1988.
8. Mather LE, Meffin PJ: Clinical pharmacokinetics of pethidine. Clinical
Pharmacokinetics 3: 352-368, 1978.
9. Mather LE: Pharmacokinetic studies of meperidine. Advance in Pain
Research and Therapy, vol 8 Eds., KM Foley, CE Inturrisi: Raven Press,
New York pp 155-165, 1986.
10. Mauro VF, Bonfiglio MF, Spunt AL: Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia. Clinical Pharmacy 5:837-839, 1986.
11. Sherman S, Lehman GA: Opioids and the sphincter of Oddi. Gastrointestinal Endoscopy 40:1, 105-6, 1994.
12. Vermeulen LC, Bollinger KA, Antonopoulos J, Meek PD, Goshman LM, Ploetz PA. Medication use anagement: multifaceted approach to medication use policy development: the restriction of meperidine. Pharmacy Practice Management Quarterly, 16(4):66-78, 1997.